News

News 21.10.2025 Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced...

News 16.10.2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million) Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million) EBITDA...

News 15.10.2025 Zurich, Switzerland - 14.10.2025 Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug (formerly ALXN2220, NI006) for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who were previously enrolled in the proof-of-concept study NI006-101 (NCT04360434). Cliramitug is an investigational human monoclonal antibody designed to...

News 15.10.2025 Schlieren, ZH/Alpharetta — Kuros Biosciences AG, based in Schlieren, marks the first step toward commissioning a new plant in the US with a symbolic ribbon-cutting ceremony. The official opening will follow in July 2026. According to a press release, Kuros Biosciences took the "first step" in its US expansion by cutting...

Events, External events
Event date: 11.02.2026 We are excited to invite you to the LS2 Annual Meeting 2026, Switzerland’s premier life sciences event, held at the Irchel Campus of the University of Zürich from February 11 to 12, 2026! The meeting will kick off with the Young Scientists’ Satellite on February 10. We hope to bring...